Physician profile
Carolyn Chen
NPI 1669671723
$2,973.47
in general payments reported to CMS, 2019-2025
19 companies · $631 in 2025
The $631 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $14.90 · 2021: $333 · 2022: $479 · 2023: $736 · 2024: $585 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $659.41 | 2021-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $451.21 | 2022-2025 | Alphagan P, Lumigan, Ozurdex |
| Sun Pharmaceutical Industries INC. | $338.12 | 2019-2025 | |
| Genentech USA, INC. | $309.95 | 2022-2025 | Vabysmo |
| Oyster Point Pharma, INC. | $173.41 | 2022-2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $172.02 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $167.87 | 2022-2024 | Vyzulta, Zylet, Lotemax Sm |
| Alimera Sciences, INC. | $163.77 | 2019-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $115.09 | 2023-2025 | Izervay |
| Alcon Vision LLC | $91.13 | 2022-2025 | Tryptyr, Rocklatan, Simbrinza |
| Biotissue Holdings INC. | $75.00 | 2024-2025 | |
| Harrow Eye, LLC | $56.64 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $41.60 | 2019-2022 | |
| Amgen INC. | $40.73 | 2024-2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $34.79 | 2023 | Syfovre |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $26.66 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $19.10 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $18.82 | 2021 | |
| Allergan, INC. | $18.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.